Drug withdrawal from the Internet has become the norm, and hundreds of drugs have been disqualified from the Internet

Recently, the Gansu Provincial Centralized Purchasing Network for Drugs and Medical Consumables issued the "Notice on the Relevant Matters Concerning the Cancellation of the Eligibility for the Application for Revocation of Drugs and the Qualification of the Online Bidding (The 44th Batch)"
.
The content of the notice shows that 123 drugs from 54 companies have recently submitted applications for withdrawal due to production line transformation, rising costs, shortage of raw materials, and suspension of production, which cannot guarantee the normal supply of medical institutions in our province
.
It is understood that in fact, on February 25, the Gansu Provincial Public Resources Trading Center issued a "Notice on Matters Concerning the Cancellation of the Eligibility for Applying for the Revocation of Drugs that Win the Bid on the Internet", announcing that it will be cancelled from March 3, 2022.
63 withdrawn drugs have the qualification to be listed on the Internet
.
The content of the notice shows: Recently, 63 medicines from 31 companies have submitted applications for withdrawal due to production line transformation, rising costs, shortage of raw materials, and suspension of production
.
The withdrawn drugs include a variety of dosage forms, of which there are many injections, up to 27, including glucose and sodium chloride injection, 10% glucose injection, 0.
9% sodium chloride injection and other basic infusions
.
The second is the capsule dosage form
.
The manufacturing enterprises involved include Eli Lilly Suzhou Pharmaceutical, Shanxi Qianyuan Pharmaceutical, Hubei Minkang Pharmaceutical, Huazhong Pharmaceutical,
etc.
In addition to Gansu Province, on April 1, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding Procurement Network also issued the "Notice on Publicizing Some Enterprises' Revocation of Platform-Based Procurement Qualifications".
The notice shows that a total of 77 varieties have been withdrawn from the network, involving 42 domestic and foreign pharmaceutical companies.
, including CSK, Novartis, Qilu,
etc.
Judging from the list, the 77 varieties of the application for withdrawal from the network include not only commonly used clinical drugs, but also some heavy tumor drug varieties
.
On the whole, all provinces have established mechanisms for withdrawing from the network, and a large number of drugs have been withdrawn from the network since the beginning of this year
.
In addition to scrapping drugs that could not be supplied stably, closing down unfinished bargain purchases, and accepting drugs, large-scale treatment was also carried out, especially for drugs without purchase records
.
For example, on January 12, the Ningxia Hui Autonomous Region Public Resource Trading Network issued a notice to cancel the qualification for winning the bid (listing on the Internet) for drugs that have no actual storage transaction records within one year in the Ningxia Pharmaceutical Purchasing Platform.

.
It is reported that as many as 5,358 products have been cancelled this time, including ribavirin, penicillin sodium for injection, levofloxacin hydrochloride injection, cefuroxime sodium for injection, loratadine and other commonly used western medicines; there are also Niuhuangjiedu tablets.
, Xinnaokang Capsules, Banlangen Granules, Tongxuan Lifei Granules, Bazhen Yimu Pills and other traditional Chinese medicines
.
There are also as many as 1,439 companies involved, including Chia Tai Tianqing, Kelun Pharmaceuticals, and Yangtze River Pharmaceuticals
.
The analysis believes that with the continuous advancement of the centralized drug procurement organized by the state, the competition among pharmaceutical companies will become more and more intense
.
At the same time, drug withdrawal from the Internet will also become the norm
.
This will undoubtedly have many impacts on the future development of the pharmaceutical industry.
The pharmaceutical industry may usher in a new pattern, and at the same time, it will increasingly test the company's strategic decision-making capabilities and product layout capabilities
.
In this context, pharmaceutical companies can only give full play to their own advantages, speed up the research and development of innovative products, have leading products with core competitiveness, accelerate the expansion of product line layout, and make every effort to do a good job of consistency evaluation, and actively participate in national and provincial drug concentration Purchasing can better respond to market changes and pressures
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.